The Value of Detection of Her2 Gene Amplification in Different Stages of Bladder Cancer
|
|
- Caren French
- 5 years ago
- Views:
Transcription
1 The Value of Detection of Her2 Gene Amplification in Different Stages of Bladder Cancer Thesis for the fulfillment of M.D degree in Pathology By Dr. Heba Khalil Mohamed Under supervision of Prof. Dr. Ali Fouad El Hindawi Professor of Pathology and Head of Tumor Marker Unit - Pathology Department Faculty of medicine-cairo university Prof. Dr. Maha Mosaad Professor of Pathology Faculty of medicine-cairo university Prof. Dr. Olfat Ali Hammam Professor of Pathology Theodor Bilharz Research Institute Cairo University 2012
2 Acknowledgment I wish to express my deep gratitude to Prof. Dr. Ali Fouad El Hindawi, Prof. of pathology, and head of Tumor Marker unit, Faculty of Medicine, Cairo University for his constant guidance, Constructive supervision and following the performance and progress of this thesis. I would also like to express my profound gratitude and deep appreciation toward Prof. Dr. Maha Mosaad Prof. of pathology, Cairo University for her effective supervision and great help during the histopathological, immunohistochemical and FISH in this thesis and for her continuous encouragement throughout the course of the thesis. I am greatly indebted to Prof Dr. Olfat Ali Hammam, am, Prof. of pathology, Theodor Bilharz Research Institute for suggesting the topic of this research, setting up the plan and her valuable assistance in reading, revision, discussion and statistical studies of the results during the whole work in this thesis. I really enormously benefited from her creative thinking, valuable suggestions and constructive criticism. No words are sufficient to express my gratitude towards all the staff members of Pathology Department, Theodor Bilharz Research Institute, for their sincere encouragement and support throughout the study. Special thanks for technicians of Pathology Department, Theodor Bilharz Research Institute, for their help and cooperation. Finally, I appreciate the cooperation of our dear patients, I hope this work offers them a chance for their better health which they deserve. Heba Khalil M. Khalil
3 Abstract: The Her2/neu oncoprotein, also known as (NEU, EGFR2, or ERBB2) is one of the members of the Epidermal Growth Factor Receptor (EGFR) family, which includes EGFR or (ERBB1), EGFR3 or (HER3/ERBB3) and EGFR4 or (HER4/ERBB4), is known to contribute to physiological mechanisms of cell proliferation by intrinsic tyrosine-kinase-activity. Overexpression has been shown for several tumors and is known to influence malignant cell proliferation, metastasis and angiogenesis (Wülfing et al., 2005). Although the genes contain extracellular, transmembrane and intarcellular domains, the regions of greatest homology are the kinase domains contained within an intracellular domain. However, the genes have distinct properties: HER2 has strong kinase activity but has no identified ligand and ERBB3 lacks kinase activity due to substitutions in critical TK (Tyrosine Kinase) domain residues (Citri et al., 2003). All are capable of forming homodimers (with the possible exception of ERBB3) and heterodimers. EGFR and HER2 are dysregulated in many human cancers and play important roles in cancer development and progression (Slamon et al., 1978). Recent studies indicate the role of Her2 in the development of numerous types of human cancer. Her2 overexpression and/or amplification have been detected in 10%-34% of invasive breast cancers and correlates with clinical outcome, poor prognosis, and constitute a predictor factor of poor response to chemotherapy and endocrine therapy (Kaptain et al., 2001). Her2 Overexpression and/or amplification have been also detected in gastric carcinoma (Gravalos and Jimeno 2008), colonic carcinoma (Schuell et al., 2006) and bladder cancer (Eltze et al., 2005). Trastuzumab (Herceptin) is a monoclonal antibody which specifically targets Her2 protein by directly binding the
4 extracellular domain of the receptor. Trastuzumab enhances survival rates in both primary and metastatic Her2-positive breast cancer patients (Smith et al., 2007). The efficacy of Trastuzumab in breast cancer patients has led to investigate its antitumour activity in patients with Her2-positive cancers, including bladder cancers. Bladder carcinoma is one of the commonest malignancy in the Egypt. Approximately 93% of these tumors are derived from the epithelial lining and are termed urothelial or transitional cell carcinomas (Droller 1998). Similar to other epithelial malignancies, patients with carcinoma of the bladder have a high rate of survival (90%) if the disease is diagnosed at an early stage. However, the presence of even superficial invasion into the muscularis propria results in a dramatic fall in the 5-year survival rate to < 50%. Patients with metastatic bladder carcinoma are treated with systemic chemotherapy, but their disease remains a virulent disorder for which there is no cure. The disease is highly lethal, with a 5-year survival rate of < 5% (Thrasher and Crawford 1993). The standard treatment for patients with muscle-invasive bladder carcinoma is a radical cystectomy. Approximately 50% of patients who undergo this procedure ultimately will develop recurrences and die of their disease. Therefore, attempts have been made to reduce this recurrence rate by translating chemotherapy advances in metastatic disease into studies of neoadjuvant or adjuvant chemotherapy for patients with high-risk, organ-confined tumors. Unfortunately, after a decade of clinical trials exploring these issues, the role of chemotherapy in this patient remains largely undefined despite results of a recent U.S. Cooperative Group Trial (Southwest Oncology Group trial 8710)
5 reporting that neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin prior to cystectomy significantly improved survival compared with cystectomy alone (Lehmann et al., 2001). Fortunately, in the past decade, several new chemotherapeutic agents with activity and increased tolerability in bladder carcinoma have become available, including the nucleoside analog gemcitabine and the taxane paclitaxel. Several recent chemotherapy trials in patients with carcinoma of the bladder have incorporated paclitaxel in an attempt to improve outcomes and toxicity profiles. Those trials demonstrated that paclitaxelbased combinations are feasible, tolerable, and efficacious (Pectasides et al., 2000). Studies of bladder carcinoma that have analyzed gene amplification and/or increased protein expression of HER2 by a variety of methods have shown mixed results. Whereas several studies have reported its association with higher disease stage, increased tumor progression, and increased metastasis (Korkolopoulou et al., 1997). Other studies have shown no additional prognostic value over established criteria, such as disease stage and tumor grade (Mellon et al., 1996). Key words: Urinary bladder-her2- Immunohistochemistry-FISH.
6 LIST OF CONTENTS List of tables i List of figures ii,iii List of histograms iv List of abbreviations V Aim of the work 1 Review of literature.. 2 Material and methods 34 Results 42 Discussion. 78 Summary and Conclusion 85 Recommendations. 90 References.. 91 Arabic Summary 105
7 LIST TABLES Table (1): Sex distribution in different studied groups. Table (2): Age distribution in different studied groups. Table (3): HER2 protein immunoexpression in different bladder lesions. Table (4): HER2 gene expression by FISH in different bladder lesions. Table (5): HER2 protein immunoexpression in malignant lesions. Table (6): HER2 gene expression by FISH in malignant lesions. Table (7): HER2 protein immunoexpression by IHC in bilharzial associated and non bilharzial associated bladder lesions. Table (8): HER2 gene expression using FISH in Bilharzial and Non Bilharzial Bladder lesions. Table (9): HER2 protein immunoexpression in different stages of malignant lesions. Table (10): HER2 gene expression in different stages of malignant lesions. Table (11): HER2 protein immunoexpression in different stages of transitional cell carcinoma. Table (12): HER2 gene expression in different stages of transitional cell carcinoma. Table (13): HER2 protein immunoexpression in different stages of squamous cell carcinoma. Table (14): HER2 gene expression by FISH in different stages of Squamous Cell Carcinoma. Table (15): HER2 protein immunoexpression in different grades of transitional cell carcinoma. Table (16): HER2 gene expression in different grades of transitional cell. Table (17): HER2 protein immunoexpression in different grades of squamous cell carcinoma. Table (18): HER2 gene expression in different grades of Squamous Cell Carcinoma i
8 LIST OF FIGURES Fig. (1): Structure of the HER2 protein. Fig. (2): A diagram showing nucleus with DNA strands (Fluorescent in situ hybridization-wikipedia, the free encyclopedia.htm). Fig. (3): A diagram showing mechanism of FISH (Fluorescent in situ hybridization- Wikipedia, the free encyclopedia.htm). Fig. (4): A diagram showing steps of FISH (Fluorescent in situ hybridization- Wikipedia, the free encyclopedia.htm). Fig (5): Fluorescence microscope (Olympus x51) using 3 filters (green (WB), red (FITC) and DAPI). Fig. (6): A control case showing normal urothelial lining (H& E, x 100). Fig. (7): A control case showing negative HER2 protein immunoexpression, score 1+( IHC, Her2/neu, DAB, x200). Fig. (8): A case of Bilharzial cystitis showing living and dead Bilharzia ova in Lamina propria (H& E, x 10). Fig. (9): A case of polypoid cystitis showing negative HER2 protein immunoexpression, score 1+ in normal urothelial lining (IHC, HER2/neu, DAB, x100). Fig. (10): A case of non invasive low grade papillary urothelial carcinoma (H&E, X20). Fig. (11): A case of non invasive urothelial carcinoma, Grade II, showing strong HER2 protein immunoexpression in tumor cells (IHC, HER2/neu, DAB, x 200). Fig. (12): A case of infiltrating high grade urothelial carcinoma, grade III, infiltrating lamina propria and muscle (H&E, x100). Fig. (13): A case of moderately differentiated Bilharzial associated squamous cell carcinoma, strongly positive for HER2 protein ore 3+ (IHC, HER2/neu, DAB, x40). Fig. (14): A case of poorly differentiated urothelial (Transitional) cell carcinoma. Showing equivocal HER2 protein immunoexpression in tumor cells (IHC,HER2/neu DAB, x400). Fig. (15): A case of infiltrating poorly differentiated urothelial (Transitional) cell carcinoma strongly positive for HER2 protein immunoexpression, score 3+ (IHC, HER2/neu, DAB, x100). Fig. (16): A case of keratinizing moderately differentiated squamous cell carcinoma (H&E, X200). Fig. (17): A case of poorly differentiated urothelial (Transitional) cell carcinoma. Showing equivocal HER2 protein immunoexpression in tumor cells (IHC, HER/neu, DAB, x200). Fig. (18): A control case showing negative HER2 gene expression, two green signals and two red signals (FISH, HER2/neu gene, x1000). Fig. (19): A case of papillary urothelial (Transitional) cell carcinoma, positive for HER2 gene amplification, showing red clusters (FISH, HER2/neu ii
9 gene, x1000). Fig. (20): A case of squamous cell carcinoma, negative for HER2 gene amplification (FISH, HER2/neu gene, x1000). Fig. (21): A case of urothelial (Transitional) cell carcinoma, positive for HER2 gene amplification, showing red clusters (FISH,HER2 /neu gene, x1000). Fig. (22): A case of invasive urothelial (Transitional) cell carcinoma, negative for HER2 gene amplification ( FISH, HER2/neu gene, x1000). Fig. (23): A case of Bilharzial squamous cell carcinoma, positive for HER2 gene amplification, showing more than 6 red signals per cell ( FISH, HER2/neu gene x1000). Fig. (24): A case of squamous cell carcinoma, negative for HER2 gene amplification, FISH (FISH, HER2/neu, gene, x1000). Fig. (25): A case of high grade urothelial carcinoma showing polysomy of chromosome 17, more than 2 green signals in the cell (FISH, HER2/neu, gene, x1000) iii
10 LIST OF HISTOGRAMS Hist. (1): Sex distribution in different studied lesions. Hist. (2): Age distribution among different studied lesions. Hist. (3): HER2 Protein Immunoexpression in different Bladder lesions. Hist. (4):HER2 gene expression using FISH in different bladder lesions Hist. (5): HER2 protein immunoexpression in malignant lesions. Hist. (6): HER2 gene expression using FISH in malignant lesions. Hist. (7): HER2 protein immunoexpression in bilharzial and non bilharzial lesions. Hist. (8): HER2 gene expression in bilharzial and non bilharzial lesions. Hist. (9): HER2 protein immunoexpression in different stages of malignant lesions. Hist. (10): HER2 gene expression in different stages of malignant lesions. Hist. (11): HER2 protein immunoexpression in different stages of Transitional Cell Carcinoma. Hist. (12): HER2 gene expression in different stages of transitional cell carcinoma. Hist. (13): HER2 protein immunoexpression in different stages of squamous cell carcinoma Hist. (14): HER2 gene expression in different stages of squamous cell carcinoma. Hist. (15): HER2 protein immunoexpression in different grades of TCC. Hist. (16): HER2 gene expression in different grades of Transitional Cell Carcinoma. Hist. (17): HER2 protein immunoexpression in different grades of Squamous Cell Carcinoma. Hist. (18): HER2 gene expression in different grades of squamous cell carcinoma iv
11 LIST OF ABBREVIATIONS TCC: Transitional Cell Carcinoma SqCC: Squamous Cell Carcinoma CIS: Carcinoma In Situ EGFR: Epidermal Growth Factor Receptor (HER/erbB) FISH: Fluorescence In situ Hybridization. IHC: Immunohistochemistry TUR: Trans-Uretheral Resection Non. Bil.Cystitis:Non Bilharzial cystitis Bil.Cystitis: Bilharzial Cystitis. Non Bil.TCC: Non Bilharzial Transitional Cell Carcinoma. Bil.TCC: Bilharzial Transitional Cell Carcinoma. Non Bil.SqCC: Non Bilharzial Squamous Cell Carcinoma Bil.SqCC: Bilharzial Squamous Cell Carcinoma. v
12 Aim of work AIM OF THE WORK This work aims at: - To study the relationship between the expression of HER2 protein by using immunohistochemistry and gene amplification by using Fluorescence In situ Hybridization technique in different types and stages of cancer bladder. - To study the incidence of HER2 expression with the transitional cell neoplasia compared to squamous cell neoplasia in Bilharzial associated and Non Bilharzial associated cases. 1
13 Review of literatures Bladder Cancer Epidemiology of bladder cancer Urinary bladder cancer is a common disease worldwide. At any point in time 2.7 million people have a history of urinary bladder cancer (Ploeg et al., 2009). Urinary bladder cancer ranks ninth in worldwide cancer incidence (Ferlay et al., 2005). It is the seventh most common malignancy in men and seventeenth in women. Approximately 357,000 new bladder cancer cases (274,000 males and 83,000 females) occurred worldwide yearly (Parkin, 2008). Urinary bladder cancer is the second most common malignancy of all genitourinary tumors after prostate cancer and is nearly three times more common in men than in women (Jemal et al., 2005). In Egypt: Carcinoma of the bladder is the foremost oncologic problem, Egypt has the highest recorded incidence rate of bladder cancer in the world, and the incidence of 37.1 per 100,000 males is almost two times higher than in Western communities (Ferlay et al., 2005). At the National Cancer Institute (NCI), it constitutes 30.3% of all cancers, 40.6% of male cancers, and 14.3% of female cancers (El-Bolkainy et al., 2000). According to the International Agency for Research on Cancer (IARC) statistical study: Egyptian bladder cancer cases were 8842 male and 1911 female with an incidence crude rate reached 24.9 per for males and 5.5 per for females while deaths from bladder cancer were 7972 male and 1714 female with mortality crude rate reached 22.5 per for males and 5 per for females. In the same statistical study Egypt ranked first among Northern African and Arabian African countries in urinary bladder cancer incidence and mortality rates in both males and females (Ferlay et al., 2005). 2
14 Pathology of Bladder Cancer Review of literatures WHO Histological Classification of Tumors of the Urinary Tract (Eble et al., 2004) I. Transitional Cell Neoplasms Infiltrating urothelial carcinoma with squamous differentiation with glandular differentiation with trophoblastic differentiation Nested Microcystic Micropapillary Lymphoepithelioma-like Lymphoma-like Plasmacytoid Sarcomatoid Giant cell undifferentiated Non-invasive urothelial neoplasia Urothelial carcinoma in situ Non-invasive papillary urothelial carcinoma, high grade Non-invasive papillary urothelial carcinoma, low grade Non-invasive papillary urothelial neoplasia of low malignant potential Urothelial papilloma Inverted urothelial papilloma II. Squamous Cell Neoplasms A. Squamous cell carcinoma B. Verrucous carcinoma C. Squamous cell papilloma III. Glandular Neoplasms Adenocarcinoma Enteric Mucinous Signet-ring cell Clear cell A. Villous adenoma IV. Neuroendocrine Tumors A. Small cell carcinoma B. Carcinoid 3
15 Review of literatures C. Paraganglioma V. Melanocytic Tumors A. Malignant melanoma B. Nevus VI. Mesenchymal Tumors A. Rhabdomyosarcoma B. Leiomyosarcoma C. Angiosarcoma D. Asteosarcoma E. Malignant fibrous histiocytoma F. Leiomyoma G. Haemangioma H. Other VII. Haematopoietic and Lymphoid Tumors A. Lypmphoma B. Plasmacytoma VIII. Miscellaneous Tumors A. Carcinoma of Skene, Cowper and Littre glands B. Metastatic tumors and tumors extending from other organs The main two histological types of bladder cancer are identified: the transitional cell carcinomas (TCC), related to cigarette smoking and most prevalent in Western and industrialized countries, and the squamous cell carcinomas (SqCC), which are more frequently seen in some Middle Eastern and African countries, where urinary schistosomiasis is an endemic disease. I) Transitional Cell (Urothelial) Carcinoma (TCC): It comprises 90% of primary tumors of the bladder and 30-40% of carcinomas associated with shistosomiasis. In past decades, increased incidence of transitional cell carcinoma associated with shistosomiasis has been reported (Cardillo et al., 2003). Transitional cell carcinoma is defined as any malignant epithelial tumor of the bladder consisting entirely, partly or focally of anaplastic urothelium. These tumors differ from normal urothelium by having an increased number of epithelial cell layers with papillary folding of the mucosa, loss of cell polarity, 4
16 Review of literatures abnormal cell maturation from the basal to superficial layers, giant cells, nuclear crowding, increased nuclear-to-cytoplasmic ratio, prominent nucleoli, clumping of chromatin, and an increased number of mitoses (Koss et al., 1975). Transitional cell carcinomas manifest in a variety of patterns of tumor growth, including papillary, sessile, infiltrating, nodular, mixed, and flat intraepithelial growth (carcinoma in situ). Approximately 70% of bladder tumors are papillary, 10% are nodular, and 20% are mixed (Cardillo et al., 2003). A. Papillary transitional cell (Urothelial) carcinoma: It is defined as an urothelial tumor that does not invade beyond the basement membrane. According to Mostofi et al., 1999, it is graded on a scale of I to III in an ascending manner of severity as follows: 1. Grade-I TCC: The epithelium of grade I urothelial carcinomas has an orderly appearance, but with easily recognizable variations of architectural and cytological features. Mitoses are infrequent, but may occur at any level of the epithelium, usually the basal third. Nuclear grooving is prominent and a perpendicular orientation of basal cell is usually evident. Superficial cells may be present but flattened. 2. Grade-II TCC: They exhibit an intermediate degree of abnormality. They are designated from grade I by a predominantly disordered architectural pattern, but with retention of some elements of organization, e.g. polarity and nuclear uniformity. 3. Grade-III TCC: The papillae show complete disorder with loss of polarity and commonly loss of superficial cells, marked variation of all nuclear parameters and usually numerous irregularly distributed mitoses. With higher grade 5
17 Review of literatures tumors, there is variable epithelial thickness due to increasing loss of cellular cohesions. B. Infiltrating transitional cell (Urothelial) Carcinoma: It is defined as an urothelial tumor that invades beyond the basement membrane. As with the papillary tumors, these are graded on an I to III scale, depending on the degree of nuclear anaplasia. The most anaplastic areas determine the tumor grade (Fine et al., 2005). The WHO panel recognized that some centers prefer to use a two grade system for papillary and infiltrating transitional cell carcinoma that is designated as low grade and high grade lesions. The low grade lesions correspond to WHO grade I tumors, the high grade lesions correspond to WHO grade II and III tumors (Fine et al., 2005). C. Carcinoma in situ (CIS): It is a non-papillary, i.e. flat, lesion in which the surface epithelium contains cells that are cytologically malignant (Eble et al., 2004). De novo (primary) carcinoma in situ accounts for less than 1-3% of urothelial neoplasms, but is seen in 45-65% of invasive urothelial carcinoma (Wolf et al., 1987). Data suggest that de novo (primary) CIS is less likely to progress to invasive disease than secondary CIS (Orozco et al., 1994). II) Squamous Cell Carcinoma (SqCC): Squamous cell carcinoma of the urinary bladder, though uncommon in Europe and the United States, is the most common variety of bladder tumor in countries where urinary bilharziasis prevails (El- Sebaie et al., 2005). A. SqCC in the bilharzial bladder: The highest incidence of SqCC of the bilharzial bladder is in Egypt. In a report by Ghoneim et al., 1997, SqCC constituted 59% of 1026 cystectomy specimens at the Mansoura Urology and Nephrology Centre in the period between 1969 and Bilharzial eggs were seen in 85% of the 1026 specimens. 6
18 Review of literatures The tumor is diagnosed in the fifth decade, and five times more common in men than women. Bladder carcinogenesis is probably related to bacterial and viral infections, commonly associated with bilharzial infestation rather than the parasite itself. The presentation is often with irritative bladder symptoms and hematuria, and many patients present at an advanced stage, although most tumors are of low and moderate grades. At cystoscopy tumors are predominantly nodular and usually arise from the upper vesical hemisphere. Lymph-node metastasis occurs in 19% and significantly decreases survival; radical cystectomy remains the main treatment, giving a 5-year survival rate of 50% (Shokeir, 2004). B. SqCC in the non bilharzial bladder: The non-bilharzial type occurs in Western countries and represents <5% of all vesical tumours; it occurs most often in the seventh decade with a slight male predominance. The principal predisposing factor is prolonged indwelling urethral catheterization in patients with spinal cord injury and the main symptom is haematuria. Patients are usually diagnosed at an advanced stage and most of the tumours are of moderate and high grades. At cystoscopy tumours are predominantly ulcerative and commonly involve the trigone and lateral walls. Although distant metastasis is infrequent (8-10%) the prognosis is grave and most patients die after failure of loco-regional control; radical cystectomy provides the best therapy. To avoid non-bilharzial SqCC, patients with spinal cord injury should be free of catheterization if possible. The outcome can be improved by early detection with frequent cytology, cystoscopy and biopsy (Shokeir, 2004). Verrucous Carcinoma It is a special type of squamous carcinoma of border-line malignancy that is almost exclusively associated with S. hematobium infection representing 3% of total squamous bladder cancers. The majority of lesions are usually locally advanced (Khaled, 1993). 7
19 Review of literatures Tumor Staging Staging systems for cancer bladder have been based upon observation of the clinical course of different tumors in association with their depth of penetration through the bladder wall at presentation. Penetration is based primarily on tissues obtained at the time of transurethral resection TUR biopsy. However, physical examination and radiological imaging can provide complementary information. Bladder tumor treatment, prognosis, and the likelihood of metastatic disease are strongly depending on the depth of primary tumor invasion (Mundy, 1999). Currently, the most recent staging system is the one developed jointly by the World Health Organization (WHO) in 2004, also termed Tumor-Node- Metastasis (TNM). This staging system enables simultaneous description of primary tumor extent (T), status of lymph nodes (N), and extent of distant metastasis (M). The following table shows the 2004 TNM classification for staging of bladder cancer (Eble et al., 2004). 8
20 Review of literatures T T --- Primary Tumor Tx: Primary tumor cannot be assessed. T0: No evidence of tumor. Ta: Non-invasive papillary carcinoma. Tis: Carcinoma in situ: flat tumor. T1: Tumor invades subepithelial connective tisuue. T2: Tumor invades muscle T2a-Tumor invades superficial muscle (inner half). T2b-Tumor invades deep muscle (outer half). T3: Tumor invades perivesical tissue T3a-Microscopically T3b-Macroscopically (extravesical mass). T4: Tumor invades any of: prostate, uterus, vagina, pelvic wall, abdominal wall T4a-Invasion of the surrounding organs, (e.g.: prostate, uterus & vagina). T4b-Invasion of the pelvic wall, abdominal wall. N N --- Regional Lymph Nodes Nx: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes none more than 5 cm in greatest dimension. N3: Metastasis in a lymph node more than 5 cm in greatest dimension. M M --- Distant Metastasis Mx: Distant metastasis cannot be assessed. M0: Absent distant metastasis. M1: Distant metastasis. 9
The pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationPathology of bladder cancer in Egypt; a current study.
Pathology of bladder cancer in Egypt; a current study. Thesis Submitted for partial fulfillment of Master degree in urology By Mohamed Atef Mohamed Ahmed M.B.B.CH Supervised by Prof.Dr.: Omar Mohamed Abdel-
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationSpectrum of Lesions in Cystoscopic Bladder Biopsies -A Histopathological Study
AJMS Al Ameen J Med Sci (2 012 )5 (2 ):1 3 2-1 3 6 (A US National Library of Medicine enlisted journal) I S S N 0 9 7 4-1 1 4 3 C O D E N : A A J M B G ORIGI NAL ARTICLE Spectrum of Lesions in Cystoscopic
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationEtiology and diagnosis of bladder cancer
Etiology and diagnosis of bladder cancer Introduction Incidence: the most common urothelial tumor, representing the 2 nd most common urological tumor in men (4 th in overall frequency) and the 1 st in
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationUpdate on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
More informationPathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)
Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions
More informationNeoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath
Neoplasia 2018 Lecture 2 Dr Heyam Awad MD, FRCPath ILOS 1. List the differences between benign and malignant tumors. 2. Recognize the histological features of malignancy. 3. Define dysplasia and understand
More informationJ of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 3/ Issue 24/June 16, 2014 Page 6628
ADENOCARCINOMA OF BLADDER-SIGNET RING CELL MUCINOUS VARIANT S. Senthil Kumar 1, D. Prem Charles 2, B. Krishnaswamy 3, P. Viswanathan 4, S. Sarath Chandran 5 HOW TO CITE THIS ARTICLE: S. Senthil Kumar,
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationTypes of bladder cancer
There are three main types of bladder cancer: Urothelial bladder cancer Squamous cell cancer Adenocarcinoma of the bladder There is more information about how we treat the different types of bladder cancer
More information2% of all malignancies Male predominance Patients usually more than 60 years old
Benign Bladder Tumors Transitional Cell Papilloma 2-3% Inverted Papilloma Rare Malignant Transitional (Urothelial) Carcinoma 90% Carcinoma In-Situ (By Itself) 5-10% Squamous Cell Carcinoma 3-7% Adenocarcinoma
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 16 Done by Waseem Abo-Obeida Corrected by Zeina Assaf Doctor Maha Shomaf MALIGNANT NEOPLASMS The four fundamental features by which benign and malignant tumors can be distinguished are: 1- differentiation
More informationONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III.
ONCOLOGY Csaba Bödör Department of Pathology and Experimental Cancer Research 2018. november 19., ÁOK, III. bodor.csaba1@med.semmelweis-univ.hu ONCOLOGY Characteristics of Benign and Malignant Neoplasms
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationAfterword: The Paris System for Reporting Urinary Cytology
Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology
More informationRecently, there has been an increasing incidence among women and younger persons
Bladder Tumors Benign Transitional Cell Papilloma 2-3% Inverted Papilloma Rare Malignant Transitional (Urothelial) Carcinoma 90% Carcinoma In-Situ (By Itself) 5-10% Squamous Cell Carcinoma 3-7% Adenocarcinoma
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationEpithelial tumors. Dr. F.F. Khuzin, PhD Dr. M.O. Mavlikeev
Epithelial tumors Dr. F.F. Khuzin, PhD Dr. M.O. Mavlikeev Epithelial tumors Tumors from the epithelium are the most frequent among tumors. There are 2 group features of these tumors: The presence in most
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological
More informationNormal Morphology. Anatomic Considerations. Normal Urothelial Histology and Cytology
1 Normal Morphology Anatomic Considerations The urinary tract can be divided into three regions: the kidney; the calyces, pelves and ureters (upper collecting system or upper tract); and the bladder and
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationMody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
More information2007 Multiple Primary and
2007 Multiple Primary and Histology Coding Rules Beyond the Basics Florida Cancer Data System Annual Conference Tampa, FL July 26,2007 Steven Peace, CTR Westat Carol Johnson, CTR NCI SEER Peggy Adamo,
More informationA neoplasm is defined as "an abnormal tissue proliferation, which exceeds that of adjacent normal tissue. This proliferation continues even after
NEOPLASIA Neoplasia is a very important topic in pathology because neoplasms are both common and serious diseases. A neoplasm literally means a new growth, and this term is used interchangeably with a
More informationNEOPLASIA-I CANCER. Nam Deuk Kim, Ph.D.
NEOPLASIA-I CANCER Nam Deuk Kim, Ph.D. 1 2 Tumor in the hieroglyphics of the Edwin Smith papyrus (1,600 B.C., Breasted s translation 1930) 3 War on Cancer (National Cancer Act, 1971) 4 Cancer Acts in Korea
More informationPart II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by
Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More information2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseudocapsule
GENITOURINARY PATHOLOGY Kathleen M. O Toole, M.D. Renal Cell Carcinoma 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow Necrotic Mass Grossly is a Bright
More informationImmunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors
Romanian Journal of Morphology and Embryology 2006, 47(2):175 179 ORIGINAL PAPER Immunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors E. TRAŞCĂ 1), R.
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationIV. Tumours of the urinary bladder
Bull. Org. mond. Sant 11974. 50, 43-52 Bull. Wld Hlth Org. J IV. Tumours of the urinary bladder A. M. PAMUKCU 1 Tumours of the urinary bladder are uncommon in all domestic animals except cattle in certain
More informationVulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho
Carcinoma Vulva & Vagina Subdivisi Onkologi Ginekologi Bagian Obgin FK USU Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva
More informationTransitional Cell Papilloma 2-3% Inverted Papilloma Rare
BLADDER TUMORS Benign Transitional Cell Papilloma 2-3% Inverted Papilloma Rare Malignant Transitional (Urothelial) Carcinoma90% Carcinoma In-Situ (By Itself) 5-10% Squamous Cell Carcinoma 3-7% Adenocarcinoma
More information3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours
60 3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours Compilation and editing and of this volume: Prof. Chandu de Silva (Consultant Histopathologist) List of contributors Consultant
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Urethra and Periurethral Glands
Protocol for the Examination of Specimens From Patients With Carcinoma of the Urethra and Periurethral Glands Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition,
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with
More informationBLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR
Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationUnknown Slides Conference
Unknown Slides Conference Jae Y. Ro, MD, PhD Weill Medical College of Cornell Univ. The Methodist Hospital, and UT MD Anderson Cancer Center Houston, TX November 9, 2013 Amman, Jordan 25 th Congress of
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More informationGUIDELINES ON PENILE CANCER
GUIDELINES ON PENILE CANCER (Text updated March 2005) G. Pizzocaro (chairman), F. Algaba, S. Horenblas, H. van der Poel, E. Solsona, S. Tana, N. Watkin 58 Penile Cancer Eur Urol 2004;46(1);1-8 Introduction
More informationUnusual Variants of Bladder Cancer Cristina Magi-Galluzzi, MD, PhD
Unusual Variants of Bladder Cancer Cristina Magi-Galluzzi, MD, PhD Director of Genitourinary Pathology, Professor of Pathology, Lerner College of Medicine Cleveland Clinic Objectives Update on variants
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationMale genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.
Male genital tract tumors Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital. adenocarcinoma Prostate Cancer most common male cancer in western countries more detected in
More informationUrological Tumours 1 Kidney tumours 2 Bladder tumours
Urological Tumours 1 Kidney tumours 2 Bladder tumours Tim Bracey SpR Histopathology Derriford Hospital Kidney tumours What are we going to talk about?! Anatomy of urinary tract! Types of kidney tumours!
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationEAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationRENAL CELL CARCINOMA 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseud
GENITOURINARY PATHOLOGY Kathleen M. O Toole Toole, M.D. RENAL CELL CARCINOMA 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a
More informationPatient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3)
Carcinoma of the Bladder Histopathology Reporting Guide Cystectomy, Cystoprostatectomy and Diverticulectomy Specimen Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of
More informationMultiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More information!! 2 to 3% of All New Visceral Cancers.!! Peak Incidence is 6th Decade!! M:F = 2:1
!! Kathleen M. O Toole, M.D.!! 2 to 3% of All New Visceral Cancers!! Peak Incidence is 6th Decade!! M:F = 2:1!! Grossly is a Bright Yellow, Necrotic Mass with a Pseudocapsule 1 !!Conventional RCC! Clear
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationQ&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda
Collecting Cancer Data: Bladder March 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding Moment Bladder Overview Multiple Primary Histology Rules Collaborative Stage Data Collection System Diagnostic,
More informationEnrollment Form: Pancreas
Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification
More informationUpdate on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationCondyloma Acuminatum. Mimics of Bladder Cancer. Squamous Papilloma. Squamous epithelium in bladder
Mimics of Bladder Cancer Murali Varma Cardiff, UK wptmv@cf.ac.uk Squamous epithelium in bladder Non-keratinising vaginal type mucosa common in trigone region in women Normal variant Sarajevo Nov 2013 Squamous
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationIndex 179. Genital tract contaminants, 17, 20, 22, 150 papilloma virus-infected cells, 47 squamous cells, sources of, 7
Index Accuracy of urinary cytology, 166 Acute inflammatory cells, 38 catheter sample, 39 herpes simplex infections, 44 carcinomas, 104, 105 non-viral inclusions, 52, 53 voided urine, 17 Adenocarcinoma
More informationSmall Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition
Small Intestine Protocol applies to all invasive carcinomas of the small intestine, including those with focal endocrine differentiation. Excludes carcinoid tumors, lymphomas, and stromal tumors (sarcomas).
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,
More informationTitleSarcomatoid carcinoma of the bladde.
TitleSarcomatoid carcinoma of the bladde Author(s) Takashi, Munehisa; Sakata, Takao; N Tatsuya; Miyake, Koji Citation 泌尿器科紀要 (1992), 38(1): 67-70 Issue Date 1992-01 URL http://hdl.handle.net/2433/117446
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationJesse K. McKenney, MD
Jesse K. McKenney, MD Outline Microscopic anatomy of the urinary bladder Diagnosing invasion Subtle patterns (variants) of carcinoma Clinically important variants of carcinoma Microanatomy of Bladder Initial
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More information